Your browser is no longer supported. Please, upgrade your browser.
Settings
ARQT Arcutis Biotherapeutics, Inc. daily Stock Chart
ARQT [NASD]
Arcutis Biotherapeutics, Inc.
Index- P/E- EPS (ttm)-2.84 Insider Own0.90% Shs Outstand37.59M Perf Week5.25%
Market Cap1.01B Forward P/E- EPS next Y-3.86 Insider Trans-1.39% Shs Float35.68M Perf Month-6.73%
Income-90.50M PEG- EPS next Q-0.88 Inst Own88.60% Short Float4.40% Perf Quarter-29.84%
Sales- P/S- EPS this Y-118.10% Inst Trans3.29% Short Ratio12.72 Perf Half Y-30.49%
Book/sh5.56 P/B4.61 EPS next Y-6.60% ROA-58.20% Target Price43.50 Perf Year-
Cash/sh5.67 P/C4.52 EPS next 5Y22.90% ROE-108.70% 52W Range17.10 - 40.88 Perf YTD17.66%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-39.70% Beta-
Dividend %- Quick Ratio11.80 Sales past 5Y- Gross Margin- 52W Low44.15% ATR1.66
Employees29 Current Ratio11.80 Sales Q/Q- Oper. Margin- RSI (14)45.42 Volatility7.61% 6.85%
OptionableNo Debt/Eq0.00 EPS Q/Q-130.90% Profit Margin- Rel Volume0.49 Prev Close25.65
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume123.53K Price24.65
Recom2.00 SMA20-0.98% SMA50-5.60% SMA200-10.71% Volume9,060 Change-3.90%
Feb-25-20Initiated Guggenheim Buy $36
Feb-25-20Initiated Goldman Neutral $30
Feb-25-20Initiated Cowen Outperform $55
Feb-25-20Initiated Cantor Fitzgerald Overweight $50
Sep-16-20 09:00AM  
Sep-15-20 09:00AM  
Sep-08-20 09:00AM  
Aug-11-20 04:02PM  
Aug-10-20 09:00AM  
Aug-04-20 09:00AM  
Aug-03-20 09:00AM  
Jul-31-20 09:00AM  
Jul-27-20 09:00AM  
Jul-20-20 09:00AM  
Jul-15-20 05:07PM  
Jul-13-20 09:00AM  
Jun-22-20 11:47AM  
09:00AM  
Jun-10-20 04:05PM  
Jun-01-20 09:00AM  
May-27-20 09:00AM  
May-12-20 04:05PM  
Apr-27-20 08:30AM  
Apr-21-20 09:00AM  
Mar-23-20 08:30AM  
Mar-16-20 08:37AM  
Mar-05-20 08:30AM  
Mar-03-20 08:30AM  
Feb-19-20 08:30AM  
Feb-14-20 08:00PM  
Feb-13-20 08:30AM  
Feb-04-20 04:05PM  
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical cream formulation of roflumilast that is in Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of ARQ-151 for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical small molecule inhibitor of janus kinase type 1 for hand eczema and other inflammatory dermatoses; and ARQ-255, a topical formulation of ARQ-252 designed to reach deeper into the skin to the postulated site of inflammation in alopecia areata. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was founded in 2016 and is headquartered in Westlake Village, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Welgus Howard G.DirectorSep 15Option Exercise0.581,222709177,400Sep 16 05:57 PM
Welgus Howard G.DirectorSep 01Option Exercise1.682,2003,696178,378Sep 02 11:48 AM
Welgus Howard G.DirectorSep 01Sale24.382,20053,643176,178Sep 02 11:48 AM
Welgus Howard G.DirectorAug 20Option Exercise1.685,0008,400176,178Aug 21 02:19 PM
Welgus Howard G.DirectorAug 18Option Exercise1.685,0768,528171,178Aug 19 05:48 PM
Welgus Howard G.DirectorAug 14Option Exercise0.586,1103,545166,102Aug 18 04:12 PM
Welgus Howard G.DirectorAug 03Option Exercise1.682,8004,704162,725Aug 05 05:11 PM
Welgus Howard G.DirectorAug 03Sale25.632,80071,764159,992Aug 05 05:11 PM
Smither John WChief Financial OfficerJun 11Option Exercise1.6814,87524,999123,840Jun 15 03:15 PM